Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;31(9):975-985.
doi: 10.1111/iju.15499. Epub 2024 Jun 1.

Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023

Kohei Hashimoto  1 , Takeo Kosaka  2 , Naoki Terada  3 , Takahiro Kimura  4 , Norio Nonomura  5 , Hiroyoshi Suzuki  6 , Hiroji Uemura  7
Affiliations

Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023

Kohei Hashimoto et al. Int J Urol. 2024 Sep.

Abstract

Objective: To evaluate and compare the voting results of Japanese urologists with the global panel at the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Methods: Among the 198 questions discussed at the APCCC 2022, the APCCC-JAPAN 2023 focused on 14 key questions related to the management of advanced prostate cancer with insufficient high-level evidence based on their relevance to the Japanese cohort. A panel of six prostate cancer experts addressed these 14 questions and presented the latest evidence to Japanese urologists who voted on-site using a web-based system. The results were compared with those of APCCC 2022.

Results: This study found significant differences in the voting results between Japanese urologists and the global panel regarding several crucial issues related to advanced prostate cancer management. These differences were those observed in treatment preferences, monitoring strategies, and treatment choices in specific clinical scenarios. These findings highlight the need for a nuanced approach tailored to the unique challenges with considerations of the Japanese healthcare environment.

Conclusions: APCCC-JAPAN 2023 provides valuable insights into the current clinical issues surrounding the management of advanced prostate cancer in Japan. The partial divergence in the consensus between Japanese urologists and the global panel underscores the importance of a context-specific approach. The results of this study provide practical guidance for physicians facing complex challenges and should be used to inform decision-making in the management of advanced prostate cancer.

Keywords: APCCC‐JAPAN 2023; advanced prostate cancer; management.

PubMed Disclaimer

References

REFERENCES

    1. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer. Part I: intermediate‐/high‐risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022. Eur Urol. 2023;83:267–293.
    1. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer‐metastatic and/or castration‐resistant prostate cancer: report of the advanced prostate cancer consensus conference (APCCC) 2022. Eur J Cancer. 2023;185:178–215.
    1. Fujita K, Suzuki H, Hinata N, Miura Y, Edamura K, Tabata KI, et al. Management of patients with advanced prostate cancer in Japan: ‘real‐world’ consideration of the results from the advanced prostate cancer consensus conference. Transl Androl Urol. 2022;11:1771–1785.
    1. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez‐Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration‐sensitive prostate cancer. N Engl J Med. 2017;377:352–360.
    1. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone‐sensitive prostate cancer. J Clin Oncol. 2019;37:2974–2986.

Publication types

LinkOut - more resources